Belite Bio at H.C. Wainwright conference: tinlarebant nears FDA review

Belite Bio presented at the H.C. Wainwright 28th Annual Global Investment Conference, detailing the progress of Tinlarebant, its oral drug for Stargardt disease. The company stated that Tinlarebant is nearing FDA review, and highlighted strong clinical data, a large potential patient base, and a solid cash position. However, they also acknowledged that placebo progression in the main trial was slower than expected, which could impact the regulatory review process.

The FDA package for Tinlarebant includes natural history data from the ProgStar study, fellow-eye analysis, imaging evidence, and other data to support approval. Belite Bio reported $780 million in cash and expected operating costs of about $450 million over three years, with approximately 20,000 clinically diagnosed Stargardt patients in the U.S. and 10,000 genetically confirmed.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.